PluriPLUR -1.67%25 ROE % is 0.00% as of Mar. 2026. GuruFocus rates PLUR with a GF Score™ of 25/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,255 Biotechnology companies, Pluri ranks worse than 79681.2% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Pluri's annualized net income for the quarter that ended in Mar. 2026 was $-22.19 Mil. Pluri's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $-16.61 Mil. Therefore, Pluri's annualized ROE % for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for Pluri's ROE % or its related term are showing as below:
PLUR's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.34 * Ranked among companies with meaningful ROE % only.
Pluri (NAS:PLUR) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Pluri ROE % Related Terms
Pluri ROE % Historical Data
* Premium members only.
The historical data trend for Pluri's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pluri's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pluri ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pluri's ROE % distribution charts can be found below:
* The bar in red indicates where Pluri's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.
Pluri (PLUR) has a ROE % of 0.00% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pluri and its competitors. According to the industry distribution chart, Pluri ranks #999999 out of 1255 companies in the Biotechnology industry.
Is Pluri's ROE % too high?
Pluri's current ROE % is 0.00%. Based on the distribution chart, Pluri ranks #999999 out of 1255 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pluri has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pluri's ROE % compare to VTGN and PTN?
According to the Biotechnology industry distribution chart, Pluri ranks #999999 out of 1255 companies for ROE %. This places Pluri in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pluri and its competitors. Pluri's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Based on GuruFocus' analysis, Pluri (PLUR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $2.06 — trading 68.1% below its estimated fair value. The current ROE % is 0.00%. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Pluri (PLUR), the current ROE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pluri (PLUR) Overvalued in 2026?
Based on GuruFocus' analysis, Pluri stock appears to be undervalued.
The current stock price of $2.06 is trading 68.1% below its estimated GF Value™ of $6.46.
GuruFocus considers Pluri to be Possible Value Trap.
Key valuation signals for PLUR:
ROE %: 0.00%
GF Value™: $6.46 vs. price of $2.06 (68.1% below fair value)
No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score
Get the complete analysis for PLUR
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLUR has been successfully added to your 
